US 12,085,569 B2
Plasma autoantibody biomarkers for basal like breast cancer
Joshua LaBaer, Chandler, AZ (US); Jie Wang, Glendale, AZ (US); Ji Qiu, Chandler, AZ (US); Garrick Wallstrom, Mesa, AZ (US); Karen Anderson, Scottsdale, AZ (US); Jin Park, Phoenix, AZ (US); and Jonine Figueroa, Edinburgh (GB)
Assigned to ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, Scottsdale, AZ (US); and THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, Bethesda, MD (US)
Filed by ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, Scottsdale, AZ (US); and THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, Bethesda, MD (US)
Filed on Sep. 8, 2022, as Appl. No. 17/940,883.
Application 17/940,883 is a continuation of application No. 16/743,906, filed on Jan. 15, 2020, granted, now 11,525,831.
Application 16/743,906 is a continuation of application No. 15/534,203, abandoned, previously published as PCT/US2015/064792, filed on Dec. 9, 2015.
Claims priority of provisional application 62/089,631, filed on Dec. 9, 2014.
Prior Publication US 2023/0079737 A1, Mar. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/574 (2006.01); C07K 16/30 (2006.01); C12Q 1/6886 (2018.01); G01N 33/564 (2006.01); C12N 15/11 (2006.01)
CPC G01N 33/57415 (2013.01) [C07K 16/3015 (2013.01); C12Q 1/6886 (2013.01); G01N 33/564 (2013.01); C12N 15/11 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01)] 7 Claims
 
1. A method comprising:
contacting a serum or plasma sample obtained from a human subject to a panel of tumor antigens, wherein said human subject is a female patient less than 50 years old; and
detecting binding of at least two tumor antigens with antibodies in the serum or plasma, wherein the antigens are detectably labeled and the at least two tumor antigens are RNF216, PPHLN1, PSRC1, and TRIM21.